A Feasibility Study of Bevacizumab Plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer

PURPOSE: Bevacizumab confers benefits in metastatic breast cancer but may be more effective as adjuvant therapy. We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin–cyclophosphamide (ddAC)→nanoparticle albumin−bound (nab)-paclitaxel in human epidermal growth factor receptor 2...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: McArthur, Heather L., Rugo, Hope, Nulsen, Benjamin, Hawks, Laura, Grothusen, Jill, Melisko, Michelle, Moasser, Mark, Paulson, Matthew, Traina, Tiffany, Patil, Sujata, Zhou, Qin, Steingart, Richard, Dang, Chau, Morrow, Monica, Cordeiro, Peter, Fornier, Monica, Park, John, Seidman, Andrew, Lake, Diana, Gilewski, Theresa, Theodoulou, Maria, Modi, Shanu, D’Andrea, Gabriella, Sklarin, Nancy, Robson, Mark, Moynahan, Mary Ellen, Sugarman, Steven, Sealey, Jane E., Laragh, John H., Merali, Carmen, Norton, Larry, Hudis, Clifford A., Dickler, Maura N.
Format: Artigo
Sprog:Inglês
Udgivet: 2011
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4994894/
https://ncbi.nlm.nih.gov/pubmed/21350003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1969
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker